Please login to the form below

Not currently logged in
Email:
Password:

Abbott christens new pharma company AbbVie

Will spin out the research-based pharmaceutical company by the end of this year

Abbott Laboratories has decided on AbbVie as the name for the research-based pharmaceutical company it intends to spin out by the end of this year.

Abbott announced last October that it intended to separate into two publicly-traded companies, one with its pharmaceutical assets and the other with a diversified range of medical products, including nutritionals, medical devices and diagnostics.

AbbVie's name is derived from a combination of Abbott and "vie", which references the Latin root "vi" meaning life, said the company.

"The beginning of the name connects the new company to Abbott and its heritage of pioneering science," said Richard Gonzalez, who was previously named as chief executive of the new pharma company.

"The 'vie' calls attention to the vital work the company will continue to advance to improve the lives of people around the world," he added.

The AbbVie logo and graphic identity will be unveiled when the new company is officially launched. Meanwhile, the Abbott brand name is staying with the medical products company, which will have around $22bn in annual revenues.

AbbVie's product portfolio will account for almost $18bn in annual revenue, and include major brand such as Humira (adalimumab) for arthritis, Trilipix/Tricor (fenofibrate) and Niaspan (niacin) for high cholesterol, HIV drug Kaletra (lopinavir/ritonavir) and prostate cancer therapy Lupron (leuprolide acetate).

Analysts have suggested that AbbVie will face a challenging few early years, as it stands to lose patent protection for Tricor, Niaspan and Humira between now and 2016.

The new company will also absorb R&D assets in therapeutic areas such as hepatitis C, immunology, chronic kidney disease, women's health, oncology and neuroscience, which will "help drive future growth", according to the company.

It will start life with four projects in phase III, including gonadotropin-releasing hormone (GnRH) antagonist elagolix, partnered with Neurocrine Biosciences and in testing for endometriosis, as well as bardoxolone for chronic kidney disease, cancer drug elotuzumab and daclizumab for multiple sclerosis.

22nd March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Strategic North

Strategic North is an insight driven healthcare strategic marketing agency, which offers you something a little bit different. Our purpose...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....

Infographics